Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Spontaneous tumor hemorrhage (TH) is frequently observed in solid tumors including human hepatocellular carcinoma (HCC). TH implies fast-growing and worse tumor immunological microenvironment; however, the underlying mechanism remains largely unknown.
CLEC1B
is a signature gene highly associated with
tumor progression
. PD-L1 expression is a key biomarker predictive of immune checkpoint therapies, which showed astonishing effect on various types of tumor. We assume that, in HCC, TH may closely associate with the expression of these two molecules. In this study, 136 patients with HCC were enrolled. qRT-PCR showed that
CLEC1B
expression is significantly lower in HCC tumor tissue. Immunohistochemistry of HCC tissue microarrays demonstrated that PD-L1
high
and
CLEC1B
low
expressions were significantly correlated with TH and clinicopathological features indicating worse HCC progression. According to univariate/multivariate analysis, a combination of PD-L1
high
and
CLEC1B
low
expression was an independent prognostic factor indicating the poor outcome. The prognostic value of PD-L1
high
and
CLEC1B
low
was validated by Cox proportional-hazard analyses. Collectively, tumor with TH is closely associated with
CLEC1B
low
& PD-L1
high
expression, which may imply high response of PD-L1/PD-1 immune checkpoint therapies.
CLEC1B
may be a potential therapeutic target for PD-L1/PD-1 immunotherapy. PD-L1
high
and
CLEC1B
low
can be a valuable prognosis factor implying worse clinical outcomes.
...
PMID:CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage. 2952 32